• Progression of the portfolio with FDA IND clearance to initiate clinical activities for mdc-TJK and mdc-ANG entering preclinical
• Launch of Animal Health activities
• Revenue increase and strong cash position in line with expectations
Post-closing events
• Up to 19 M$ grant from the Bill & Melinda Gates Foundation for mdc-WWM
• Antipsychotic programs: confirmation of clinical activities start for the second long-acting injectable antipsychotic mdc-TJK and interim analysis for mdc-IRM Phase 3 in the second half of 2020